New agents for the management of castration-resistant prostate cancer;Agentes nuevos para el manejo de cáncer de próstata resistente a castración

Annals of Pharmacotherapy

Volumn 46, Issue 11, 2012, Pages 1518-1528

  Cersosimo, Robert J ^a,b  

^a NORTHEASTERN UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Abiraterone; Cabazitaxel; Castration resistant prostate cancer; Hormone refractory prostate cancer; Sipuleucel T

Indexed keywords

ABIRATERONE; ABIRATERONE ACETATE; CABAZITAXEL; CYTOCHROME P450 3A; DOCETAXEL; GONADORELIN AGONIST; GRANULOCYTE COLONY STIMULATING FACTOR; LUTEINIZING HORMONE; MITOXANTRONE; PREDNISONE; SIPULEUCEL T; TESTOSTERONE;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; ANDROGEN SYNTHESIS; ANEMIA; ANTIBODY TITER; AREA UNDER THE CURVE; ARTHRALGIA; ASTHENIA; ASYMPTOMATIC DISEASE; BLEEDING; BONE MARROW SUPPRESSION; BONE PAIN; BONE SCINTISCANNING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHILL; CIRCULATING TUMOR CELL; CONSTIPATION; DIARRHEA; DRUG APPROVAL; DRUG COST; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; GLEASON SCORE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERHIDROSIS; HYPERTENSION; HYPOKALEMIA; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INTENTION TO TREAT ANALYSIS; LEUKAPHERESIS; LIPID DIET; LIVER DYSFUNCTION; LIVER TOXICITY; LUTEINIZING HORMONE BLOOD LEVEL; MAXIMUM PLASMA CONCENTRATION; MYALGIA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; TACHYCARDIA; TESTOSTERONE BLOOD LEVEL; TRANSIENT ISCHEMIC ATTACK; TUMOR GROWTH;

ANDROSTENOLS; ANTINEOPLASTIC AGENTS; CASTRATION; HUMANS; MALE; PROSTATIC NEOPLASMS; TAXOIDS; TISSUE EXTRACTS;

EID: 84869222996     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R169     Document Type: Review

References (36)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Kirby M, Hirst C, Crawford ED. Characterizing the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract 2011;65: 1180-92.
3. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
4. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008;26:242-5.
5. Basch EM, Somerfield MR, Beer TM, et al. American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer. J Clin Oncol 2007;25:5313-8.
6. National Comprehensive Cancer Network. NCCN guidelines prostate cancer version 3.2012. April 2012. http://NCCN.org (accessed 2012 Jun 21).
7. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22.
8. Kantoff P, Higano CS, Berger ER, et al. Updated results of the IMPACT trial of sipuleucel-T for metastatic castration-resistant prostate cancer (CRPC) (abstract 8). Proc Amer Soc Clin Oncol Genitourinary Cancer Symp 2010. www.ASCO.org/ASCOv2/meetings/abstracts?&vmview=abst_detail_view&confID=73&abstractID=30778 (accessed 2012 Oct 30).
9. Mita AC, Denis LJ, Rowinsky EK, et al. Phase I and pharmacokinetic study of XRP6258 (PRP 116258A), a novel taxane, administered as a 1- hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009;15:723-30.
10. Reid AH, Attard G, Danila DC, et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010;28:1489-95.
11. Prescribing information. Provenge (sipuleucel-T). Seattle, WA: Dendreon Corp., June 2011.
12. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000;18:3894-903.
13. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone-refractory prostate cancer. J Clin Oncol 2006;24:3089-94.
14. Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009;115:3670-9.
15. Madan RA, Gulley JL, Fojo T, Dahut WL. Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist 2010;15:969-75.
16. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15:7412-20.
17. Beer TM, Bernstein GT, Corman JM, et al. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Clin Cancer Res 2011;17:4558-67.
18. Technology assessment. Outcomes of sipuleucel-T therapy. Prepared for the Agency for Healthcare Research and Quality. February 10, 2011. www.cms.gov/medicare-coverage-database/details/technology-assessmentsdetails.aspx?TAId=77&bc=BAAgAAAAAAAA (accessed 2012 Mar 6).
19. Food and Drug Administration April 29, 2010, approval letter - Provenge. http://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ucm210215.htm (accessed 2012 Mar 6).
20. Chambers JD, Neumann PJ. Listening to Provenge-what a costly cancer treatment says about future Medicare policy. N Engl J Med 2011; 364:1687-9.
21. Decision memo for autologous cellular immunotherapy treatment of metastatic prostate cancer (CAG-00422N). www.cms.gov/medicare-coveragedatabase/details/nca-decision-memo.aspx?NCAId=247&ver=14&NcaName=Autologous+Cellular+Immunotherapy+Treatment+of+Metastatic+Prostate+Cancer&TAId=77&IsPopup=y&bc=AAAAAAAAIAAA& (accessed 2012 Mar 6).
22. Prescribing information Jevtana (cabazitaxel). Bridgewater, NJ: Sanofi- Aventis, June 2010.
23. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147-54.
24. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial (web appendix). Lancet 2010;376:1147-54. www.sciencedirect.com/science/article/pii/S014067361061389x
25. de Bono JS, Sartor O. Cabazitaxel for castration-resistant prostate cancer- authors' reply (letter). Lancet 2011;377:122-3.
26. Cabazitaxel at 20 mg/m2 Compared to 25 mg/m2 With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer (PROSELICA). http://clinicaltrials.gov/ct2/show/NCT01308580 (accessed 2012 Feb 2).
27. Prescribing information. Zytiga (abiraterone). Horsham, PA: Centicor Ortho Biotec, June 2012.
28. Rehman Y, Rosenberg JE. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer. Drug Design Dev Ther 2012;6:13-8.
29. Danila DC, Morris MJ, de Bono JS, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxeltreated castration-resistant prostate cancer. J Clin Oncol 2010;28:1496-501.
30. Ryan CJ, Smith MR, Fong L, et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010;28:1481-8.
31. 17, 20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 2004;90:2317-25.
32. Attard G, Reid AH, A'hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009;27:3742-8.
33. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
34. de Bono JS, Attard G, Reid AH, et al. Anti-tumor activity of abiraterone acetate (AA), a CYP17 inhibitor of androgen synthesis, in chemotherapy- naïve and docetaxel pre-treated castration resistant prostate cancer (CRPC) (abstract 5005). J Clin Oncol 2008;26(suppl).
35. Ryan CJ, Shah S, Efstathiou E, et al. Phase II study of abiraterone acetate in chemotherapy-naïve metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res 2011;17: 4854-61.
36. Ryan CJ, Smith MR, De Bono JS, et al. Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naïve patients (pts) with metastatic castration-resistant prostate cancer (CRPC) (abstract LBA4518). J Clin Oncol 2012;30:(suppl).